Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 6
Submit an article Journal homepage
38
Views
0
CrossRef citations to date
0
Altmetric
Case Studies

Azacitidine-induced myopericarditis in acute myeloid leukemia

Mahmoud Ismayla Department of Internal Medicine, Creighton University School of Medicine, Omaha, NebraskaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9033-7835
, MDORCID Icon,
Asmini KCb Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
, MD,
Abhishek Thandrac Division of Cardiovascular Medicine, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska
, MD,
Nattapong Sricharoenc Division of Cardiovascular Medicine, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska
, MD &
Amy Arounic Division of Cardiovascular Medicine, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska
, MD
Pages 849-851 | Received 23 Jun 2022, Accepted 04 Aug 2022, Published online: 18 Aug 2022

  • DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971.
  • Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012;120(25):4945–4951. doi:10.1182/blood-2012-06-434639.
  • Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. JCO. 2009;27(11):1850–1856. doi:10.1200/JCO.2008.17.1058.
  • Mahida H, Gharia B, Ugoeke N, Maludum O, Asif A, Calderon D. Evaluation of cardiovascular adverse events associated with ibrutinib, venetoclax and idelalisib used in treatment of chronic lymphocytic leukemia. Circulation. 2018;138(Suppl 1):A11835–A11835.
  • Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343(19):1388–1398. doi:10.1056/NEJM200011093431908.
  • Newman M, Malla M, Gojo I. Azacitidine-induced pericarditis: a case series. Pharmacotherapy. 2016;36(4):443–448. doi:10.1002/phar.1733.
  • Bibault JE, Cambier N, Lemahieu JM, Quesnel B, Auffret M, Rose C. Acute myocarditis induced by hypomethylating agents. J Clin Oncol. 2011;29(14):e411–e412. doi:10.1200/JCO.2010.33.4656.
  • Chen CC, Gau JP, You JY, et al. Decitabine-induced effusions. Leuk Res. 2009;33(9):150. doi:10.1016/j.leukres.2008.11.028.
  • De C, Phookan J, Parikh V, et al. Decitabine induced transient cardiomyopathy: a case report. Clin Med Insights Oncol. 2012;6:325–329. doi:10.4137/CMO.S8598.
  • Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a cancer and leukemia group B study. J Clin Oncol. 2002;20(10):2441–2452. doi:10.1200/JCO.2002.04.044.
  • Wijermans P, Lübbert M, Verhoef G, et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18(5):956–962. doi:10.1200/JCO.2000.18.5.956.
  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232. doi:10.1016/S1470-2045(09)70003-8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.